cobimetinib,vemurafenib
exelixis,roche
['solid tumor', 'cobimetinib', 'vemurafenib']
#cedarssinaicancer at #asco22. dr. rodolfo gutierrez is co-author on cobimetinib plus vemurafenib in patients with solid tumors with braf v600e/d/k/r mutation being presented at 10:09am. 
Cedars-Sinai Cancer, ranked #9 in the nation in 2021 by U.S. News & World Report.